Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
US Department of Justice
Teva
US Army
Moodys
Queensland Health
Colorcon
Deloitte
Daiichi Sankyo
Baxter

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,495,165

« Back to Dashboard

Which drugs does patent 6,495,165 protect, and when does it expire?

Patent 6,495,165 protects INSPRA and is included in one NDA.

Protection for INSPRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in twenty-seven countries.
Summary for Patent: 6,495,165
Title: Eplerenone compositions having improved bioavailability
Abstract:The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.
Inventor(s): Thosar; Shilpa S. (Des Plaines, IL), Gokhale; Rajeev D. (Waukegan, IL), Tolbert; Dwain S. (Wadsworth, IL)
Assignee: G.D. Searle & Co. (Skokie, IL)
Application Number:10/101,361
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use;

Drugs Protected by US Patent 6,495,165

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-002 Sep 27, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,495,165

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,863,902 Immediate release eplerenone compositions ➤ Subscribe
6,410,054 Immediate release eplerenone compositions ➤ Subscribe
6,534,093 Immediate release eplerenone compositions ➤ Subscribe
7,157,101 Micronized eplerenone compositions ➤ Subscribe
6,592,902 Controlled release eplerenone compositions ➤ Subscribe
6,558,707 Immediate release eplerenone compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,495,165

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 1329494 ➤ Subscribe
China 1230179 ➤ Subscribe
Czech Republic 20011942 ➤ Subscribe
Germany 69911240 ➤ Subscribe
Denmark 1135139 ➤ Subscribe
Eurasian Patent Organization 200100519 ➤ Subscribe
European Patent Office 1135139 ➤ Subscribe C01135139/01 Switzerland ➤ Subscribe
Iceland 2325 ➤ Subscribe
Spain 2207977 ➤ Subscribe
Hong Kong 1041641 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Fuji
Colorcon
Teva
Johnson and Johnson
Fish and Richardson
Dow
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot